RedHill Biopharma Announces Last Patient Visit in BEKINDA® Phase II Study for IBS-D

World News: . []

Top-line results are expected in September 2017 The randomized double-blind placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDARHB-102 12 mg in 127 US patients with diarrhea-predominant irritable bo wel syn...

More news and information about RedHill Biopharma Ltd.

Published By:

Thomson Reuters: 13:00 GMT Monday 17th July 2017

Published: .

Search for other references to "redhill" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers